直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 117489
タイトル別表記
Effects of canagliflozin on WBC counts
著者
Tanaka, Atsushi Saga University
Imai, Takumi Osaka Metropolitan University
島袋, 充生 Fukushima Medical University KAKEN研究者をさがす
Nakamura, Ikuko Saga-Ken Medical Centre Koseikan
Matsunaga, Kazuo Imari-Arita Kyoritsu Hospital
Ozaki, Yukio Fujita Health University
Minamino, Tohru Juntendo University
Node, Koichi Saga University
キーワード
Chronic heart failure
Sodium–glucose cotransporter 2 inhibitor
White blood cell
資料タイプ
学術雑誌論文
抄録
Aims/Introduction: Clinical evidence is lacking about the influence of sodium–glucose cotransporter 2 inhibitors on white blood cell (WBC) counts, a commonly used and widely available marker of inflammation. The aim of the present analysis was to assess the effect of canagliflozin relative to glimepiride on WBC counts.
Materials and Methods: This was a post-hoc subanalysis of the CANDLE trial (Effects of Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure: A Randomized Trial; UMIN000017669), an investigator-initiated, multicenter, open-label, randomized, controlled trial. A total of 233 patients with type 2 diabetes and concomitant heart failure were randomly assigned to either canagliflozin (n = 113) or glimepiride (n = 120) treatment for 24 weeks. Overall, patient baseline characteristics were as follows: mean ± standard deviation age, 68.6 ± 10.1 years; hemoglobin A1c, 7.0 ± 0.9%; left ventricular ejection fraction, 56.7 ± 14.4%; and median N-terminal pro-brain natriuretic peptide, 252 pg/mL (interquartile range 96–563 pg/mL). The mean baseline WBC counts were 6704 cells/μL (95% confidence interval 6,362–7,047) in the canagliflozin group and 6322 cells/μL (95% confidence interval 5,991–6,654) in the glimepiride group. There were no significant differences between treatment groups in terms of changes in WBC counts from baseline to weeks 4 and 12. In contrast, a group difference (canagliflozin minus glimepiride) from baseline to week 24 was significant (mean difference − 456 cells/μL [95% confidence interval −774 to −139, P = 0.005]).
Conclusions: Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure.
掲載誌名
Journal of Diabetes Investigation
ISSN
20401124
cat書誌ID
AA12488319
出版者
Asian Association for the Study of Diabetes|John Wiley & Sons
13
12
開始ページ
1990
終了ページ
1999
発行日
2022-09-16
権利情報
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系